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Comprehensive neuro-rehabilitation of the children with 
mental problems improved their clinical and emotional back-
ground, memory and cognitive functions. EEG and NEC ex-
amination marked the trends in recovery of inter-hemispheric 
connections and in normalization of the bioelectrical activity in 
the brain.
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The objective to identify appropriate outcome measures 
to use in clinical trials or observational studies. Natural history 
data of patients with the heterogeneous juvenile/adult form of 
glycogen storage disease type II (GSDII) are useful to evaluate 
enzyme replacement therapy (ERT).
We evaluated several outcome measures before and during 
ERT, such as a series of timed and graded functional tests i.e. 
Gait, Stairs, Gowers, Chair (GSGC) score, the Six-Minute Walk 
Test (6MWT), Forced Vital Capacity.
During an observational study we monitored a series of 32 
patients using these outcome measures at 1 year after ERT and 
observed a partial but significant improvement. A significant 
decrease was observed in Gait time and time to raise from the 
chair and total GSGC score. A gain of function was observed 
in few cases.
Important, crucial topics seem to be: the use of different 
functional parameters in determining the efficacy of ERT, since 
not all juvenile/adult patients respond similarly, and, reliable 
outcomes of treatment.
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Laminopathies are a group of genetic diseases caused by 
mutations in the nuclear protein lamin A/C or in related pro-
teins. A group of laminopathies targets specific tissues – tissue-
specific laminopathies –, other laminopathies affect multiple 
tissues – systemic laminopathies.
The Italian Network for Laminopathies is  a group of 
Clinical and Research Centers performing clinical and molec-
ular diagnosis or biomedical research in the field of laminopa-
thies. Aims of the Italian Network for laminopathies are: to 
connect Italian Centers involved in diagnosis and biomedical 
research of laminopathies; provide information on the clini-
cal features of Laminopathies to family doctors, specialists 
and patients; provide the contact information of specialists 
involved  in the diagnosis and research of  laminopathies; 
provide updated information on biomedical research in the 
field of laminopathies; organize an Italian Registry for Lami-
nopathies containing clinical and biological data; establish a 
bank of biological material; report news on relevant events 
and meetings; report on funding opportunities in the field of 
Laminopathies research. 
The Italian Network for Laminopathies website provides 
updated  information  of  the  Network  and  of  Laminopathies-
related events.
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Myasthenia gravis (MG) is a heterogeneous disorder en-
compassing several subtypes. In our patients population, the 
most numerous and homogeneous group is represented by pa-
tients  with  a  late  onset,  seropositive,  non-thymomatous  MG 
(LO-Ab+noTh). We have analyzed the frequency of HLA-A, 
-B, - DRB1, -DQA1 and -DQB1 alleles in 81 unselected Italian 
MG patients and in 100 healthy controls. HLA allele frequencies 
were estimated by direct count and compared in a 2 × 2 contin-
gency table analysis using the Fisher exact test; p values were 
corrected for multiple comparisons according to the Bonferroni 
method (pc). When the entire MG population was considered, 
no association was found between the occurrence of the disease 
and the presence of any of the alleles analyzed. However, when 
the LO-Ab+noTh patients were compared to controls, a positive 
association of the DRB1*16 and the DQB1*0502 alleles was 
observed (pc 0,0211 and 0,00768 respectively). On the contra-
ry, the same association was not present in patients with either 
early-onset, seropositive, non-thymomatous MG, or with thy-
momatous MG. The association of DRB1*16 and DQB1*0502 
with MG has been previously reported in Italian patients with 
different features, but not in LO-Ab+noTh MG. According to 
these results, DRB1*16 and DQB1*05:02 might be considered 
as genetic markers of LO-Ab+noTh MG, while their role as pre-
disposing genetic factors for MG should be clarified by further 
investigations.